FATE THERAPEUTICS INC — Director's Dealing 2020

Nov 16, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: FATE THERAPEUTICS INC (FATE)
CIK: 0001434316
Period of Report: 2020-11-12

Reporting Person: Wolchko J Scott (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-11-12	Common stock	M	30000	$2.73	Acquired	449969	Direct
2020-11-12	Common stock	S	15202	$51.6066	Disposed	434767	Direct
2020-11-12	Common stock	S	2088	$52.6635	Disposed	432679	Direct
2020-11-12	Common stock	S	10846	$53.9835	Disposed	421833	Direct
2020-11-12	Common stock	S	1864	$54.4708	Disposed	419969	Direct
2020-11-13	Common Stock	M	10000	$2.73	Acquired	429969	Direct
2020-11-13	Common stock	S	10000	$51.03	Disposed	419969	Direct
2020-11-13	Common stock	M	9846	$7.87	Acquired	429815	Direct
2020-11-13	Common stock	S	9846	$51.03	Disposed	419969	Direct
2020-11-13	Common stock	M	10154	$6.62	Acquired	430123	Direct
2020-11-13	Common stock	S	10154	$51.03	Disposed	419969	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-11-12	Stock Option (right to buy)	$2.73	M	30000	Disposed	2027-01-03	Common Stock (30000)	Direct
2020-11-13	Stock Option (right to buy)	$2.73	M	10000	Disposed	2027-01-03	Common Stock (10000)	Direct
2020-11-13	Stock Option (right to buy)	$7.87	M	9846	Disposed	2023-08-11	Common Stock (9846)	Direct
2020-11-13	Stock Option (right to buy)	$6.62	M	10154	Disposed	2024-01-08	Common Stock (10154)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020.

F2: Represents the weighted average sale price of the shares sold ranging from $51.14 to $52.13 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

F3: Represents the weighted average sale price of the shares sold ranging from $52.15 to $53.13 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

F4: Represents the weighted average sale price of the shares sold ranging from $53.35 to $54.34 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

F5: Represents the weighted average sale price of the shares sold ranging from $54.35 to $54.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price.

F6: The shares subject to this option shall vest and become exercisable in 48 monthly installments beginning on February 4, 2017 such that this options is fully exercisable on January 4, 2021.

F7: Not applicable.

F8: This option is fully vested.